Imaging biomarkers for predicting poor prognosis of hepatocellular carcinoma: a review

Yun Zhang¹, Zi-Xing Huang¹, Jie Chen¹, Yu-Jun Shi², Han-Yu Jiang¹, Li-Kun Cao³, Bin Song¹

¹Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
²Laboratory of Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
³Department of Radiology, Peking Union Medical College Hospital (Dongdan campus), Beijing 100730, China.

Correspondence to: Prof. Bin Song, Department of Radiology, Sichuan University West China Hospital, No. 37, Guoxue Alley, Chengdu 610041, Sichuan, China. E-mail: anicesong@vip.sina.com


Received: 26 Feb 2020 First Decision: 2 Apr 2020 Revised: 21 Apr 2020 Accepted: 24 Apr 2020 Published: 16 Jun 2020

Abstract

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with a high mortality rate. Heterogeneity is the main biological characteristic of HCC, which manifests through the different biological behaviors of each phenotype and ultimately, affects patient prognosis and treatment efficacy. Various aggressive biological behaviors are considered to be associated with the poor prognosis of HCC patients including poor differentiation, microvascular invasion, intracellular fat accumulation, invasive growth, bile duct invasion or tumor thrombosis, and tumor spread and metastasis, and have been reported as prognostic biomarkers. In addition, HCC results from multifactor synergistic damage, and various factors related to genetics, molecular pathology and immunohistochemistry such as β-catenin, Ki67, cytokeratin-19, and epithelial cell adhesion molecule have an impact on HCC differentiation and prognosis. This article is an overview of the biological behaviors that lead to poor prognosis of HCC, and the roles of morphological and quantitative noninvasive imaging biomarkers in the evaluation and prediction of these behaviors. Some common biomarkers related to genetics, molecular pathology and immunohistochemistry are also briefly summarized. It is hoped that this review will provide clinicians and radiologists with an update on the development of liver imaging, and provide directions for the combination of radiology, genetics, molecular pathology and histopathology to better predict the prognosis of HCC patients.

Keywords: Hepatocellular carcinoma, poor prognosis, biological behaviors, imaging biomarkers, genetics, molecular pathology, immunohistochemistry
INTRODUCTION
Liver cancer is the sixth most prevalent cancer and the fourth leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC), mostly due to liver cirrhosis, accounts for 75%-80% of all liver cancers[1]. Heterogeneity is the main biological characteristic of HCC, which manifests through different biological behaviors of each phenotype and ultimately, affects patient prognosis and treatment efficacy. Various aggressive biological behaviors including poor differentiation, microvascular invasion (MVI), intracellular fat accumulation, invasive growth, bile duct invasion or tumor thrombosis, and tumor spread and metastasis, have been reported to have an impact on clinical outcomes and the prognosis of HCC patients[2-6].

Liver imaging, a noninvasive method for visualizing tumor morphology and function, can provide a clear diagnosis and assessment of HCC in the presence of risk factors, and has flourished in recent decades with the potential to better depict the complex biological behaviors of HCC with relevant morphological and quantitative biomarkers[7-13]. Traditional imaging, including contrast-enhanced ultrasound, multi-phase dynamic enhanced computed tomography (CT) or magnetic resonance imaging (MRI), and fluoro-deoxy-glucose/positron emission tomography (FDG/PET), play significant roles in the characterization of HCC as most have a typical blood supply and morphological characteristics. Functional imaging, including diffusion-weighted imaging (DWI), chemical-shift MRI, magnetic resonance elastography (MRE), and MRI with liver-specific contrast, can provide cellular and metabolic information for the grading and staging of HCC[14]. Furthermore, improvements in advanced imaging analysis, including radiomics and artificial intelligence (AI), have introduced enormous potential for assessing the aggressiveness of HCC and prognostication of patients. Table 1 shows the aggressive biological behaviors associated with poor prognosis of HCC patients and their pathological basis, as well as morphological and qualitative imaging biomarkers that can be used to evaluate and predict biological behaviors. In addition, HCC is the result of multifactor synergistic damage, and various factors related to genetics, molecular pathology and immunohistochemistry also have an impact on HCC differentiation and prognosis[15].

This article reviews the imaging biomarkers for aggressive behaviors associated with a poor prognosis in HCC patients, and the roles of different imaging methods and related biomarkers in the evaluation and prediction of these behaviors [Table 2]. A better understanding of these imaging features and their correlation with pathology can help clinicians to design the most appropriate treatment plans for HCC. In addition, a combination or confrontation of imaging signs with other biomarkers may be a direction for future research to better predict the prognosis of HCC.

POOR DIFFERENTIATION
Differentiation refers to the dedifferentiation of premalignant nodules until the development of HCC itself. The degree of differentiation of HCC is the key to prognosis of HCC patients[16]. Several pathological alterations are involved in loss of differentiation in HCC such as neoangiogenesis, disordered cellular structure, impairment of Kupffer cells and hepatocytes, and increased glucose metabolism in tumor cells.

NEOANGIOGENESIS
Neovascularization provides the basis for oxygen and nutrition for tumor growth, progression and metastasis. The unpaired arteries are new vessels which form through neovascularization, and play a crucial role both in the occurrence and development of HCC[17].

As most HCCs show a typical enhancement pattern such as hyperenhancement in the hepatic arterial phase, and washout appearance in the portal venous and/or delayed phases relative to the surrounding tissue, traditional imaging technologies such as contrast-enhanced ultrasound (CEUS), dynamic contrast-enhanced
Table 1. The aggressive biological behaviors associated with poor prognosis in HCC and related imaging biomarkers

<table>
<thead>
<tr>
<th>Aggressive biological behaviors</th>
<th>Pathological basis</th>
<th>Morphological imaging biomarkers</th>
<th>Quantitative imaging biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neoangiogenesis</td>
<td>Formation of unpaired arteries</td>
<td>Hyperenhancement in the hepatic arterial phase and washout appearance in the portal venous and/or delayed phases relative to the surrounding tissue. (Contrast enhanced-US, dynamic contrast enhanced-CT or MRI)</td>
<td>Enhancement values of tumor tissue (Dynamic contrast enhanced-CT); Wash-out rate: the interval time of wash-out after injection of contrast agent. (Time-intensity curve analysis of Contrast enhanced-US); Microvascular density: $K^{C_{av}}, K_p, V_e, iAUC$ (Free-breathing DEC-MRI using gadoteric acid)</td>
</tr>
<tr>
<td>Restricted diffusion movement of water molecules within tumor cells</td>
<td>Disordered cellular structure</td>
<td>High-intensity on DWI images</td>
<td>Value of ADC (DWI, inconsistent); Value of D and ADC (DWI, IVIM); Values of MK and ADC (DKI); Tumor stiffness (MRE)</td>
</tr>
<tr>
<td>Decreased uptake of liver-specific contrast agents</td>
<td>Impairment of Kupffer cells; decrease in OATPs transporters</td>
<td>High-intensity on contrast enhanced-MRI with SPION; low-intensity on the HBP of contrast enhanced-MRI with Gd-EOB-DTPA</td>
<td>High-intensity on contrast enhanced-MRI with SPION; low-intensity on the HBP of contrast enhanced-MRI with Gd-EOB-DTPA; Increase of SUV</td>
</tr>
<tr>
<td>FDG concentration</td>
<td>Glucose metabolism increased in tumor cells</td>
<td>Uptake of fluorine-18 fluorodeoxyglucose on PET imaging</td>
<td></td>
</tr>
<tr>
<td>Microvascular invasion</td>
<td>Tumor thrombi invading microvessels</td>
<td>Larger diameter and tumor size, multiple lesions, incomplete capsule, non-smooth tumor margins, irregular rim-like arterial phase hyperenhancement, tumor multifocality, and “mosaic” architecture; hypo-intensity on the HBP of contrast enhanced-MRI Gd-EOB-DTPA</td>
<td>Higher MK value of DKI; radiomics signatures related to tumor size and intra-tumoral heterogeneity; texture analysis</td>
</tr>
<tr>
<td>Intraacellular fat accumulation</td>
<td>Steatosis occurs in the context of ischemia and hypoxia as a result of decreased portal vein and nontumoral artery flow and insufficient unpaired arteries</td>
<td>Intra-tumoral fat infiltration on in/out of phase (Chemical-shift MRI)</td>
<td>Intra-tumoral fat infiltration on in/out of phase (Chemical-shift MRI)</td>
</tr>
<tr>
<td>Invasive growth pattern</td>
<td>Invasion of cancer cells into adjacent tissues and the vascular lymphatic system</td>
<td>Infiltrative appearance; portal vein tumor thrombosis; mass with ill-defined with heterogeneous attenuation/signal intensity;</td>
<td>/</td>
</tr>
<tr>
<td>Bile duct invasion or tumor thrombosis</td>
<td>Bile duct invasion or tumor thrombosis</td>
<td>Frequently associated with obstructive jaundice, cholangitis, biliary bleeding; a soft tissue mass with proximal bile duct dilatation and a similar enhancement pattern to HCC; filling defect in the bile duct, unexpected obstruction of the bile duct, and cholangiectasis in MR cholangiopancreatography</td>
<td></td>
</tr>
<tr>
<td>Tumor spread and metastasis</td>
<td>Cell proliferation and colony formation, EMT program start-up</td>
<td>Intrahepatic micrometastasis; extrahepatic metastasis; [Imaging features of metastasis, (Contrast enhanced-US, dynamic contrast enhanced-CT or MRI, PET imaging)]</td>
<td>/</td>
</tr>
</tbody>
</table>

HCC: hepatocellular carcinoma; US: ultrasonography; CT: computed tomography; MRI: magnetic resonance imaging; DWI: diffusion-weighted imaging; IVIM: intravoxel incoherent motion; D: diffusion coefficient; ADC: apparent diffusion coefficient; MK: mean apparent kurtosis coefficient; DKI: diffusion kurtosis imaging; MRE: magnetic resonance elastography; OATPs: organic anionic transporting polypeptides; SPION: superparamagnetic iron-oxide nanoparticles; HBP: hepatobiliary phase; Gd-EOB-DTPA: gadolinium-ethoxy benzyl-diethylenetriamine penta-acetic acid; FDG: fludeoxyglucose; 18F-FDG: fluorine-18 fluorodeoxyglucose; PET: positron emission tomography; SUV: standardized uptake value; MRCP: magnetic resonance cholangiopancreatography; EMT: epithelial-mesenchymal transition; /: none

CT or MRI are used for the diagnosis of HCC. Although the typical enhancement patterns are helpful in the diagnosis of HCC, they do not provide information for the degree of differentiation in HCC. Recently, time-intensity curve analysis, a quantitative CEUS analysis method, has been used to predict the degree of HCC differentiation. Wash-out rate, one of the time-intensity curve-related parameters, is defined as the interval time of wash-out manifestation after injection of a contrast agent, which is recommended to identify tumor differentiation of HCC. As reported by Feng et al., the cut-off value of 120 s after contrast agent injection shows high accuracy for distinguishing well-differentiated HCC from poorly and
Table 2. Different imaging methods and biomarkers for predicting poor prognosis of HCC

<table>
<thead>
<tr>
<th>Biological behaviors</th>
<th>Imaging methods</th>
<th>Related imaging biomarker</th>
<th>Roles and characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoangiogenesis</td>
<td>CEUS</td>
<td>Typical enhancement features; wash-out rate (time-intensity curve analysis)</td>
<td>Surveillance and rapid diagnostic, reveal morphologic changes, convenient and radiation-free</td>
</tr>
<tr>
<td></td>
<td>DCE-CT</td>
<td>Typical enhancement features; enhancement values of tumor tissue</td>
<td>Diagnosis and differential diagnosis, CT values indicate the degree of enhancement</td>
</tr>
<tr>
<td></td>
<td>DCE-MRI</td>
<td>Typical enhancement features; microvascular density ( K_{trans}, K_p, V_p )</td>
<td>Diagnosis and differential diagnosis, provide quantitative information of blood perfusion of tumor</td>
</tr>
<tr>
<td>Restricted diffusion</td>
<td>DWI</td>
<td>Value of ADC</td>
<td>Provide information regarding physiological tissue characteristics and heterogeneity</td>
</tr>
<tr>
<td>(disordered cellular structure)</td>
<td>IVIM</td>
<td>Value of D and ADC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DKI</td>
<td>Values of MK and ADC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MRE</td>
<td>Tumor stiffness</td>
<td></td>
</tr>
<tr>
<td>Decreased uptake of liver-specific contrast agents</td>
<td>Gd-EOB-DTPA enhanced-MRI</td>
<td>Low-intensity on the HBP images (decrease of OATPs transporters)</td>
<td>Diagnosis and differential diagnosis; low sensitivity of characterization of HCC; can be used as a means of evaluating treatment response of HCC</td>
</tr>
<tr>
<td></td>
<td>PET imaging</td>
<td>Standardized uptake value</td>
<td>Early diagnosis, precise characterization, follow-up and monitoring of HCC; High sensitivity</td>
</tr>
<tr>
<td>FDG concentration</td>
<td></td>
<td></td>
<td>A sensitive indicator of tumor viability; limited to the level of diagnosis of HCC</td>
</tr>
<tr>
<td>Microvascular invasion</td>
<td>CEUS, DCE-CT/ MRI</td>
<td>Larger diameter and tumor size, multiple lesions, incomplete capsule, non-smooth tumor margins, irregular rim-like arterial phase hyperenhancement, tumor multifocality, and ‘mosaic’ architecture</td>
<td>Diagnosis and assessment. Detection and assessment of multiple morphology imaging features</td>
</tr>
<tr>
<td></td>
<td>DKI</td>
<td>Higher MK value</td>
<td>Provide quantitative information of the presence of MVI</td>
</tr>
<tr>
<td></td>
<td>Gd-EOB-DTPA enhanced-MRI</td>
<td>Hypo-intensity on the HBP images</td>
<td>Assistant diagnosis; auxiliary feature (in conjunction with other clinical indicators)</td>
</tr>
<tr>
<td></td>
<td>AI</td>
<td>Radiomics signatures related to tumor size and intra-tumoral heterogeneity; texture features</td>
<td>Intelligent and noninvasive means for the prediction of tumor heterogeneity</td>
</tr>
<tr>
<td>Intraacellular fat accumulation</td>
<td>Chemical-shift MRI</td>
<td>Intra-tumoral fat infiltration on in/out of phase</td>
<td>Monitor the presence of intra-tumoral fat infiltration in tumor; related to the histological degree of HCC; optimize disease management</td>
</tr>
<tr>
<td>Invasive growth pattern</td>
<td>CEUS; DCE-CT/ MRI</td>
<td>Infiltrative appearance; PVTT; mass with ill-defined and heterogeneous attenuation/signal intensity</td>
<td>Diagnosis and differential diagnosis; detection and assessment of multiple morphology imaging features</td>
</tr>
<tr>
<td>Bile duct invasion or tumor thrombosis</td>
<td>CEUS; DCE-CT/ MRI</td>
<td>A soft tissue mass with proximal bile duct dilatation and a similar enhancement pattern to HCC</td>
<td>Rapid diagnosis and differential diagnosis</td>
</tr>
<tr>
<td></td>
<td>MRCP</td>
<td>Filling defect in the bile duct, unexpected obstruction of the bile duct</td>
<td>Noninvasive diagnosis and characterization without contrast agents</td>
</tr>
<tr>
<td>Tumor spread and metastasis</td>
<td>CEUS-C/ MRI</td>
<td>Imaging features of metastasis</td>
<td>Limited to intrahepatic metastasis, convenient and radiation-free</td>
</tr>
<tr>
<td></td>
<td>PET imaging</td>
<td>Imaging features of metastasis</td>
<td>Intrahepatic and extrathoracic metastasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standardized uptake value</td>
<td>Show advantages in detecting distant metastasis and lymph node metastasis</td>
</tr>
</tbody>
</table>

HCC: hepatocellular carcinoma; CEUS: contrast enhanced ultrasonography; DCE-CT: dynamic contrast enhanced computed tomography; DCE-MRI: dynamic contrast enhanced magnetic resonance imaging; DWI: diffusion-weighted imaging; IVIM: intravoxel incoherent motion; D: diffusion coefficient; ADC: apparent diffusion coefficient; MK: mean apparent kurtosis coefficient; DKI: diffusion kurtosis imaging; MRE: magnetic resonance elastography; SPION: superparamagnetic iron-oxide nanoparticles; Gd-EOB-DTPA: gadolinium-ethoxy benzyl-diethylenetriamine penta-acetic acid; HBP: hepatobiliary phase; AI: artificial intelligence; PVTT: portal vein tumor thrombosis; MRCP: MR cholangiopancreatography; PET: positron emission tomography

Moderately differentiated HCC. Time-intensity curve analysis is advantageous in showing the perfusion-related characteristics of different grades of HCCs, and providing quantitative indices for the assessment of hemodynamics in tumors, which is convenient and radiation-free.

Microvascular density, as assessed by immunohistochemistry, is generally considered as an indicator of angiogenesis in malignant tumors, and is an effective prognostic marker in patients with HCC\(^{[22]}\). The DCE-MRI derived \( K_{trans}, K_p \) and \( V_p \) and the semi-quantitative parameter such as the initial area under the gadolinium concentration-time curve of the free-breathing DCE-MRI using gadoxetic acid, are highly associated with histological grades and microvascular density of HCC. The lower value of \( K_{trans} \) indicates the
histological grades of HCC, and the values of $K_{ep}$ and $V_e$ have proved to be significantly related to the tumor microvascular density. There is no difference among these DCE-MRI deprived parameters for discriminating low- from high-grade HCC in terms of their performance. This means that DCE-MRI using gadoxetic acid has great potential for the qualitative assessment of tumor neoangiogenesis and aggressiveness of HCC\textsuperscript{[23]}. 

**RESTRICTED DIFFUSION MOVEMENT OF WATER MOLECULES WITHIN TUMOR CELLS**

HCC is easier to recognize pathologically because of its distinctive cytological atypia and architectural abnormalities compared with other cirrhotic nodules\textsuperscript{[24]}. The early HCC nodule is well differentiated with an indistinct appearance, while HCC nodules that have progressed are mostly moderately differentiated with a distinct pattern and often, with a more disordered cellular structure\textsuperscript{[25,26]}.

DWI is a noninvasive technique for visualizing the 3D microscopic movement of water molecules within cells to provide information regarding physiological tissue characteristics. HCC and other cancers usually possess higher cellularity, tissue disorganization, and less extracellular space, resulting in impedance of water diffusion; therefore, DWI shows a high-intensity signal\textsuperscript{[27,28]}. In the past few years, many studies have investigated the apparent diffusion coefficient (ADC) value of DWI in predicting the differentiation of HCC\textsuperscript{[29-31]}. The conclusions however, were not consistent. This might be due to the fact that DWI cannot simply reflect the diffusion of water molecules in living tissues and capillary perfusion affects the stability of DWI performance as well.

Intravoxel incoherent motion (IVIM), as a DWI-derived novel technique, enables monitoring of tissue diffusivity and microcapillary perfusion independently\textsuperscript{[32]}. IVIM-derived parameters such as perfusion fraction (fp) and diffusion coefficient (D) combined with ADC of DWI, are reported to correlate with HCC histological grade\textsuperscript{[33-35]}. In the study by Granata et al.\textsuperscript{[33]}, ADC ($2.11 \times 10^{-3} \text{mm}^2/\text{s}$), fp (47.33%) and D ($0.94 \times 10^{-3} \text{mm}^2/\text{s}$) values were considered as the optimal cut-off points in distinguishing high- from low-grade HCCs. However, the study only included Edmondson-Steiner grade 1 to 3 HCC nodules and did not include Edmondson-Steiner grade 4 HCC, which made identification of high-grade HCCs non specific. Woo et al.\textsuperscript{[34]}, explored the relationship of ADC and D values with the histological grade of HCC. The results showed that there was a significant negative correlation between ADC and D values with the histologic grade of HCC. Moreover, the D value had better diagnostic performance than the ADC value for differentiating low- and high-grade HCC. Similar results were reported by Sokmen et al.\textsuperscript{[35]}. Therefore, both studies improved the design of the experiments, and further confirmed the results on the basis of the findings by Granata et al.\textsuperscript{[33]}, which indicated that the combination of DWI and IVIM could be used to determine the degree of HCC differentiation rather than using DWI alone. However, due to defects in the study design (i.e., retrospective study), insufficient sample size and an unclear gold standard, further prospective studies are needed.

Diffusion kurtosis imaging (DKI) is an attempt to provide a more accurate model of diffusion, and to reflect tissue heterogeneity in non-Gaussian diffusion behavior\textsuperscript{[36]}. Recently, our team validated the performance of DKI in predicting the degree of differentiation of HCC\textsuperscript{[37]}. The results showed that mean apparent kurtosis coefficient (MK) and ADC values are significantly correlated with the grade of HCC [Figure 1]. In addition, the MK value represents a higher specificity than the ADC in differentiating high-grade from low-grade HCCs. We speculated that this might be due to the fact that increased tumor cellularity results in decreased extracellular space and the restricted diffusion of water molecules, which is visually presented as decreased ADC and MD in higher-grade HCC. Furthermore, a higher MK value may be an independent risk factor for early tumor recurrence and poor prognosis in HCC patients, which might be related to the higher-grade of HCC that often tend to be more proliferative, aggressive and heterogeneous, and result in a more irregular tumor microstructure\textsuperscript{[36]}. 

Zhang et al. Hepatoma Res 2020;6:30 \url{http://dx.doi.org/10.20517/2394-5079.2020.17}
MRE is a noninvasive imaging technology for measuring the viscoelastic properties of the liver, and is reported to be capable of quantitatively assessing tumor stiffness, in addition to effectively identifying focal liver lesions. A preliminary study reported that tumor stiffness detected by MRE might be able to differentiate HCC tumor grade. However, further research is needed to verify the value of MRE in determining the degree of HCC differentiation.

DECREASED UPTAKE OF LIVER-SPECIFIC CONTRAST AGENTS

Kupffer cells, a type of macrophage that reside in the sinusoidal endothelial cells of the liver, are more likely to be distributed in early-stage or well-differentiated HCC than advanced HCC. In addition, approximately half of the administered dose of gadoxetic acid, a hepatobiliary contrast agent, is taken up by hepatocytes through the organic anionic transporting polypeptide (OATP) family and subsequently excreted into bile. Since there is progressive depletion of OATP with dedifferentiation, moderate to poorly differentiated tumors do not take up gadoxetate, and thus appear hypointense on hepatobiliary phase (HBP) of MRI.

Based on the above physiological mechanisms, liver-specific contrast agents such as superparamagnetic iron-oxide nanoparticles (SPION) and gadolinium-ethoxy benzyl-diethylenetriamine penta-acetic acid

Figure 1. A 48-year-old male with a pathologically confirmed HCC with MVI. A 7.8 cm × 6.0 cm tumor in the right posterior hepatic section shows slight hyperintensity on T2-weighted image (A), hypo-intensity relative to the surrounding liver parenchyma in hepatobiliary phase (B), and restricted diffusion on the DWI with a b-value of 700 s/mm² (C). MK map (D) shows higher signal intensity of tumor compared with that of background liver parenchyma. ADC (E) and MD (F) maps show lower signal intensity compared with that of liver parenchyma. The calculated mean values of MK, ADC, and MK for the tumor were 0.99, 1.10 × 10⁻³ mm²/s, and 1.28 mm²/s, respectively. The pathological results after tumor resection demonstrated HCC [Edmondson-Steiner (III) with positive MVI (G)]. HCC: hepatocellular carcinoma; DWI: diffusion-weighted imaging; ADC: apparent diffusion coefficient; MD: mean diffusion; MK: mean apparent kurtosis coefficient.
GD-EOB-DTPA have been produced and used in HCC diagnosis and characterization. However, SPION-enhanced MRI has lower sensitivity than GD-EOB-DTPA-enhanced MRI, especially for early HCCs without early enhancement; thus, SPION-enhanced MRI is rarely used as the contrast agent of choice in Western countries. However, SPION-enhanced MRI is still used in the East as a means of evaluating treatment response in HCC.

Decreased expression levels of OATP during multi-step hepatocarcinogenesis are inversely correlated with HCC tumor grade and aggressiveness. However, some well-differentiated HCCs and approximately 5%-12% of moderately differentiated HCCs overexpress OATPs, which is thought to be associated with a genetic alteration or of a different cellular origin. A consensus report has been reached on the application and prospects of developing GD-EOB-DTPA enhanced MRI for the early diagnosis, follow-up and outcome monitoring of HCC patients. The report indicated that hypervascularity on the arterial phase and the low signal on HBP images of GD-EOB-DTPA-enhanced MRI is more sensitive to the diagnosis of HCC when compared with CT. Moreover, HBP imaging provides critical information during the follow-up of cirrhosis-related nodules, especially for those with a diameter less than 2 cm, for predicting the histological grade of the tumor. The above research suggests that functional MRI technologies, especially the HBP scan of GD-EOB-DTPA-enhanced-MRI, will gradually become an essential means for predicting the differentiation of tumors and precise characterization of HCC.

**FDG CONCENTRATION**

The upregulation of glycogen metabolism is a prominent feature of tumor cells and it promotes survival, proliferation, and resistance to antitumor therapy. Previous studies have identified that aberrant tumor cell metabolism was associated with the expression of genes encoding enzymes leading to glycogen metabolic reprogramming and promoting HCC progression. Uptake of fluorine-18 FDG (18F-FDG) based on increased glucose metabolism in tumor cells is considered as a sensitive indicator of tumor viability. PET imaging provides the metabolic status of tumor tissues with high sensitivity and specificity. Therefore, 18F-FDG/PET, as a product of the combination of the above two mechanisms, is often used as an effective means for tumor characterization and evaluation of tumor response. Standardized uptake value, a semi-quantitative index of FDG/PET, is reported to be related to HCC-histological grade and poor prognosis of patients, with poorly differentiated or high-grade tumors showing higher intensities on FDG-PET. Moreover, the advent of novel radiopharmaceuticals recently such as 11C-choline has improved the diagnostic performance of HCC characterization and tumor grade assessment.

In comparison with PET/CT, PET/MRI shows a higher sensitivity for displaying composition and structure of tissues. PET/MRI in combination with DWI has an advantage in the differentiation of tumor tissue from non-tumor liver parenchyma, and is also helpful for understanding tumor characteristics. However, FDG-PET/MRI is mostly limited to the diagnosis of HCC and research on the value of FDG-PET MRI in predicting poor differentiation and prognosis of HCC is still lacking.

**MVI**

MVI is typically correlated with aggressive biological behaviors of HCC, and is generally considered as a risk factor for early recurrence of HCC in patients. Tumor characteristics, such as a larger diameter and tumor size, multiple lesions, incomplete capsule, and an irregular tumor margin, can be used as biomarkers in predicting the presence of MVI. Moreover, significantly increased serum levels of parameters such as α-fetoprotein, PIVKA-II, and cytokines (e.g., interleukin-35, phospho-beta1 integrin, transforming growth factor-beta1, p-Smad-2, and E-cadherin) suggest the possibility of MVI.
Multiple morphological imaging biomarkers including non-smooth tumor margins, irregular rim-like arterial phase hyperenhancement, tumor multifocality, and “mosaic” architecture, are reported to be highly correlated with MVI in HCC\(^{[62-64]}\). DWI and its-derived technologies have also shown great potential in detecting MVI in HCC. The mean and minimum ADC values of HCCs with MVI are reported to be lower than those of HCCs without MVI\(^{[65]}\). In addition, a higher MK value on DKI and irregular rim enhancement pattern are highly correlated with the presence of MVI\(^{[66]}\). Similar results were reported in our previous study\(^{[67]}\) [Figure 1]. The mechanism underlying these results may be associated with the formation of a more complex microenvironment induced by MVI, such as the presence of tumor cell proliferation, necrosis, or inflammatory damage\(^{[67]}\). Therefore, a greater packed cell structure and more irregular, heterogeneous environments are likely to occur in HCC with MVI, resulting in increased tissue diffusion, which manifest as increased MK\(^{[66,68]}\). Furthermore, hypo-intensity on HBP images on Gd-EOB-DTPA enhanced-MRI in conjunction with other clinical indicators has been proven to further improve the prediction of MVI in HCC, and is superior in predicting early recurrence and the survival rate in HCC patients\(^{[69,70]}\).

AI, a branch of computer science, has emerged as a new technology to study and develop the theory, technology and application systems for simulating, extending and expanding human intelligence. In recent years, AI has had huge potential in medical imaging and attracted considerable attention in a range of fields from tumor diagnosis to outcomes prediction. Radiomics, and its derived analyses such as texture analysis, are noninvasive methods for the prediction of tumor heterogeneity, and have shown favorable predictive accuracy of MVI status in patients with HCC\(^{[71-74]}\). Radiomics signatures associated with tumor size and intra-tumoral heterogeneity were reported to be the top-ranked indicators for MVI prediction. In addition, a radiomics nomogram incorporated with the clinical and radiological features outperform the combination of clinical and radiological features for predicting MVI and the clinical outcomes of HCC patients\(^{[73]}\).

**INTRACELLULAR FAT ACCUMULATION**

Intracellular fat accumulation, a common morphological characteristic of HCC, occurs in the context of ischemia and hypoxia due to decreased portal vein and nontumoral artery flow, and insufficient unpaired arteries\(^{[75]}\). Thus, intracellular fat accumulation is gradually increased in low-grade dysplastic nodules, high-grade dysplastic nodules, and early-stage HCC\(^{[76,77]}\). However, with regard to intra-tumoral fatty infiltration in poorly differentiated HCC, controversy exists\(^{[75,78]}\).

Chemical-shift MRI is the most commonly used technique to monitor the presence of intra-tumoral fat infiltration [Figure 2]. There is a close relationship between intracellular fatty change and MVI in HCC. MVI is more likely to occur in non-containing fatty HCCs, which means intra-tumoral fat infiltration suggests a lower risk for MVI in HCC\(^{[79]}\). Moreover, Kubota et al.\(^{[80]}\), reported that macro-vesicular steatosis HCC has a better prognosis with less portal vein invasion and a lower cumulative risk of recurrence than microvesicular steatosis HCC. More related research is necessary for detecting intra-tumoral fat infiltration, and predicting the prognosis of HCC with different histopathological characteristics in the early stage of hepatocarcinogenesis, so as to optimize disease management and promote personalized treatment.

**INVASIVE GROWTH PATTERN**

Invasive growth, defined as the invasion of cancer cells into adjacent tissues and the vascular lymphatic system, is correlated with tumor metastasis and poor prognosis. Aberrant regulation of cell migration contributes to the progression of cancer cell invasion\(^{[81]}\).

Tumors with a permeative growth pattern on CT/MRI images are frequently termed “infiltrative”, which manifest as lesions with indistinguishable margins on CT/MRI images. The Liver Imaging Reporting and Data System was developed to standardize the interpretation, reporting, and evaluation of patients at risk of developing HCC, and provides an explicit interpretation of the features of “infiltrative appearance” in
the latest version. It classifies a mass with infiltrative appearance as LR-M, which is probably or definitely malignant but not HCC specific. As the majority of tumors with infiltrative appearance in at-risk patients are HCC, the description of “infiltrative” is likely to indicate HCC in practice. Portal vein tumor thrombosis is the most helpful clue in the identification of infiltrative HCC, with accuracy ranging from 68% to 100%. The characteristic imaging manifestation of portal vein tumor thrombosis is the solid mass in the vascular cavity, which has similar enhancement features to the tumor itself on triphasic dynamic contrast-enhanced CT scan, especially with arterial phase enhancement and wash-out in the portal venous phase. Clinically, it is vital to distinguish portal vein tumor thrombosis and portal vein thrombus accurately for the intervention and treatment of patients with HCC. Imaging provides key evidence that portal vein thrombus is not enhanced in the arterial phase and occasionally, disappears after anticoagulant therapy. An ill-defined mass with heterogeneous attenuation/signal intensity is also highly indicative of the presence of an infiltrative growth pattern, which is pathologically characterized by the fusion of tumor tissue with liver parenchyma.

**BILE DUCT INVASION OR TUMOR THROMBOSIS**

HCC with bile duct invasion has a poorer prognosis since these lesions are frequently associated with obstructive jaundice, cholangitis, and biliary bleeding, in addition to portal vein thrombosis. Imaging characteristics are often used to indicate the presence of tumor thrombosis in the bile duct, including a soft tissue mass with proximal bile duct dilatation and a similar enhancement pattern to HCC, since there is a possibility of necrosis and bleeding. Tumor thrombi are characterized as a filling defect in the bile duct, unexpected obstruction of the bile duct, and cholangiectasis in MR cholangiopancreatography; however, the diagnosis of both bile duct and portal vein microthrombi remains difficult. Moreover, HCC with bile duct thrombi are poorly differentiated, unencapsulated, and invasive. These findings indicate that the timely diagnosis of bile duct invasion is crucial for the management of HCC patients.

**TUMOR SPREAD AND METASTASIS**

Tumor metastasis accounts for the main cause of death in some cancer patients. A central pivot event of this process is the start-up of a program termed the epithelial-mesenchymal transition, which plays an important
regulatory role in embryogenesis.

Treatment approaches for cancer are largely depended on both the stage of disease at diagnosis, and the patient’s performance status. Therefore, early detection of tumor spread or metastasis allows for the most appropriate treatment plans and to strive for more survival opportunities for HCC patients. Contrast-enhanced CT or MRI ensure implementation of one-step inspection and display the distinct enhancement features of metastasis better compared to ultrasound. MRI with liver-specific contrast agents improves diagnostic efficiency in the early identification of intrahepatic micrometastasis, as well as follow-up surveillance of disease development and outcomes. PET/CT has emerged as a useful modality in diagnosing extrahepatic lesions in patients with advanced HCC and assessing tumor grading. Furthermore, newly developed dual-tracer PET/CT improve and complement the advantages compared to single-tracer imaging in the evaluation of HCC metastasis, and has gradually become an alternative modality to PET/CT for detecting extrahepatic metastasis in HCC patients.

FACTORS RELATED TO GENETICS, MOLECULAR PATHOLOGY AND IMMUNOHISTOCHEMISTRY

HCC is the result of a multifactorial, synergistic damage from various biological factors related to genetics, molecular pathology, and immunohistochemistry that impact upon HCC differentiation and prognosis. With the development of liver imaging technologies, some have been detected by imaging methods and proved to be associated with imaging biomarkers [Table 3].

**β-catenin mutation**

β-catenin (CTNNB1) has been recognized as the most frequently mutated oncogene during liver cancer. Its mutation accounts for around 20%-40% of all HCC cases, and is strongly associated with larger tumors, invasive growth, and vascular invasion. In addition, HCCs with the CTNNB1 mutation show a higher grade of differentiation with frequent pseudoglandular patterns and bile production. The subgroup of hepato cellular adenomas with an active β-catenin gene show high probability of malignant transformation. Recently, several studies reported that gadoxetic acid-enhanced-MRI could be used to detect the presence of CTNNB1 mutations in HCC, because the mutation of CTNNB1 would promote

<table>
<thead>
<tr>
<th>Biomarkers</th>
<th>Role in occurrence, development and prognosis of HCC</th>
<th>Imaging biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTNNB1</td>
<td>Its mutation accounts for 20%-40% of HCC; play pivotal role in the poor prognosis of HCC; HCCs with CTNNB1 mutations show a higher grade of differentiation with frequent pseudoglandular patterns and bile production. The subgroup of hepatocellular adenomas with an active β-catenin gene show high probability of malignant transformation</td>
<td>A high enhancement ratio on HBP images of Gadoxetic acid-enhanced-MRI; a high value of ADC on DWI images</td>
</tr>
<tr>
<td>Ki-67</td>
<td>Highly correlated with staging, grading and recurrence rate of HCC; high possibility of adverse pathological features and invasive behaviors</td>
<td>The parameter Ktrans of free-breathing DCE-MRI using gadoxetic acid; T1 rt-20 min, tumor-to-muscle SI ratio, ADC value, and arterial inhomogeneous enhancement on gadoxetic acid-enhanced MRI; texture analysis on gadoxetic acid-enhanced-MRI</td>
</tr>
<tr>
<td>CK-19</td>
<td>Correlated with some clinicopathological features of tumors such as poor differentiation, metastasis, and early recurrence after resection and radiofrequency ablation</td>
<td>The arterial rim enhancement, targetoid appearance, non-peripheral “washout”, and irregular tumor margin on gadoxetic acid-enhanced MRI; lower tumor-to-liver ADC ratio, and lower tumor-to-liver SI ratio at HBP images</td>
</tr>
<tr>
<td>EpCAM</td>
<td>Involved in a series of biological processes such as cell proliferation; the overexpression of EpCAM is correlated with the angiogenesis and poor outcome of HCC; in addition, EpCAM-positive HCC is considered to be a subtype of human HCC with a poor prognosis</td>
<td>No significant correlation between irregular rim-like hyperenhancement on gadoxetic acid-enhanced-MRI and EpCAM status in HCC. Whether imaging markers can be used to indicate the EpCAM positive HCC is still unclear</td>
</tr>
</tbody>
</table>

HCC: hepatocellular carcinoma; CTNNB1: β-catenin; HBP: hepatobiliary phase; Gd-EOB-DTPA: gadolinium-ethoxy benzyl-diyethylamine penta-acetic acid; MRI: magnetic resonance imaging; ADC: apparent diffusion coefficient; DWI: diffusion-weighted imaging; SI: signal intensity; CK-19: cytokeratin-19 (CK-19); EpCAM: epithelial cell adhesion molecule
OATP expression\textsuperscript{[99,101]}. The results showed that a high enhancement ratio on HBP images of Gadoxetic acid-enhanced-MRI indicate the mutation of CTNBB1, and is closely associated with a higher differentiation grade of HCC. Moreover, a high value of ADC on DWI images could also be used as an indicator of HCC with the CTNBB1 mutation\textsuperscript{[101]}.

\textbf{Ki-67}

Ki-67 is highly correlated with the staging, grading and recurrence of HCCs. The overexpression of Ki-67 indicates a high possibility of adverse pathological features and invasive behaviors of the tumor\textsuperscript{[102]}. The parameter $K_{\text{trans}}$ of free-breathing DCE-MRI using gadoxetic acid is reported to be highly associated with Ki-67 proliferation status, and the lower value of $K_{\text{trans}}$ indicate higher Ki-67 indices and histological grades of HCC\textsuperscript{[103]}. In addition, the T1 rt-20 min, tumor-to-muscle signal intensity ratio, ADC value and the arterial inhomogeneous enhancement pattern on gadoxetic acid-enhanced-MRI are also correlated with high-Ki-67 expression\textsuperscript{[104-106]}. Furthermore, texture analysis, on the basis of gadoxetic acid-enhanced-MRI, can be applied as a tentative approach to preoperatively predict the Ki-67 status of HCC after curative resection\textsuperscript{[107]}.

\textbf{Cytokeratin-19}

Cytokeratin-19 (CK-19) are important keratin proteins expressed in liver tissue and show differential expression at different stages of physiological development of the liver. The expression of CK-19 is correlated with some clinicopathological features of tumor such as poor differentiation, metastasis, and early recurrence after tumor resection or radiofrequency ablation\textsuperscript{[108]}. The arterial rim enhancement, targetoid appearance, non-peripheral "washout", and irregular tumor margins on gadoxetic acid-enhanced MRI are reported to be effective imaging markers for evaluating the CK-19 status of HCC\textsuperscript{[109-112]}. Moreover, lower tumor-to-liver ADC and signal intensity ratios in HBP images may be helpful for predicting CK19-positive HCC with early recurrence\textsuperscript{[112]}.

\textbf{Epithelial cell adhesion molecule}

Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein expressed in most normal epithelial cells, and has been proven to be involved in a series of biological processes such as cell proliferation\textsuperscript{[111]}. It has been reported that the overexpression of EpCAM is closely correlated with the angiogenesis and poor outcomes in HCC\textsuperscript{[114]}. In addition, EpCAM-positive HCC is also considered to be a subtype of human HCC with a poor prognosis\textsuperscript{[111]}. However, the imaging biomarkers that can be used to reflect EpCAM-positive status in HCC have not been described. Recently, Rhee \textit{et al}.\textsuperscript{[63]}, used the imaging feature of irregular rim-like hyperenhancement as the poor prognostic index to explore the value of gadoxetic acid-enhanced MRI in predicting the overexpression of immunomarkers including EpCAM. However, results showed there is no statistically significant association between irregular rim-like hyperenhancement and EpCAM status in HCC. Therefore, whether imaging markers can be used to indicate EpCAM positive HCC is still unclear.

\textbf{CONCLUSION}

Hepatocarcinogenesis is a progressive and multi-stage process of molecular heterogeneity and histological dedifferentiation. The poor prognosis of HCC is strongly associated with the presence of aggressive biological behaviors in tumors. Modern noninvasive imaging technologies such as CEUS, DEC-CT/MRI and PET imaging improve the efficiency of early identification, characterization and assessment of HCC, and have been widely used for screening, diagnosis, and improving the survival of HCC patients. The increasing use of multiparametric functional methods, including DWI and its derived-technologies (IVIM, DKI), contrast enhanced-MRI with SPION or Gd-EOB-DTPA, MRE, chemical-shift MRI, radiomics and AI, for assessing tumor morphology, vascularity, cellularity, metabolic capability, texture, radiomics features, OATP function, and Kupffer cell function, thereby providing early, accurate and reliable evidence of the aggressive biological behaviors of HCC is most encouraging for clinicians and radiologists. Although liver imaging has obvious advantages in identifying the poor prognosis of HCC, currently, there is no doubt that multidisciplinary
management, including radiology, genetics, molecular pathology and histopathology would result in a more accurate and reliable diagnosis for predicting the prognosis of HCC.

DECLARATIONS

Authors’ contributions
Made substantial contributions to the conception and design of the study, and performed data analysis and interpretation: Zhang Y, Huang ZX, Chen J
Performed data acquisition, as well as provided administrative, technical, and material support: Shi YJ, Jiang HY, Cao LK, Song B

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by grants from the Research Grant of National Nature Science Foundation of China (Grant number 81771797), Science and Technology Support Program of Sichuan Province (Grant number 2017SZ0003), and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant number ZYJC18008).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES